Performance characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, version 2.0

被引:11
作者
Erali, M
Ashwood, ER
Hillyard, DR
机构
[1] Inst Clin & Expt Pathol, ARUP, Salt Lake City, UT 84108 USA
[2] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA
关键词
Hepatitis C virus; HCV RNA quantitation; COBAS AMPLICOR HCV MONITOR test; version; 2.0; QUANTIPLEX HCV bDNA test;
D O I
10.1309/KAJF-DL9G-0PNB-0FYH
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We evaluated the performance characteristics of the COBAS AMPLICOR Hepatitis C Virus (HCV) MONITOR Test, version 2.0. Dilution studies using patient specimens demonstrated a lower limit of detection of 1,000 copies per milliliter: The assay was linear from 1,000 to 1 million HCV RNA copies per milliliter. Within-run precision and between-run precision were acceptable (approximately 0.100 and 0.14 SD for log(10)[copies per milliliter-]). A comparison of this version of the test (y), with the manual AMPLICOR HCV MONITOR Test, version 1.0 (x), yielded the following Deming regression equation: y = 1.004(+/- 0.04)x + 0.654(+/- 0.22); Sy/x\D = 0.336; n = 92; r2 = 0.846; r = 0.920. Further comparison of the COBAS version 2.0 assay (x) with the QUANTIPLEX HCV bDNA Test (y) yielded the following Deming regression equation: y = 0.943 (+/- 0.130)x + 0.473 (+/- 0.717); S-y/x\D = 0.194; n = 26; r(2) = 0.600; r = 0.774. Version 2.0 detected the spectrum of HCV genotypes better than version 1.0.
引用
收藏
页码:180 / 187
页数:8
相关论文
共 21 条
  • [1] [Anonymous], 1997, HEPATOLOGY, V26, pS2
  • [2] High-tech industry marketing: The elements of a sophisticated global strategy
    Davies, W
    Brush, KE
    [J]. INDUSTRIAL MARKETING MANAGEMENT, 1997, 26 (01) : 1 - 13
  • [3] Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay, and an in-house limiting dilution method
    Hawkins, A
    Davidson, F
    Simmonds, P
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) : 187 - 192
  • [4] Comparison of quantitative HCV RNA assays in chronic hepatitis C
    Jacob, S
    Baudy, D
    Jones, E
    Xu, LZ
    Mason, A
    Regenstein, F
    Perrillo, RP
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1997, 107 (03) : 362 - 367
  • [5] Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays
    Lunel, F
    Cresta, P
    Vitour, D
    Payan, C
    Dumont, B
    Frangeul, L
    Reboul, D
    Brault, C
    Piette, JC
    Huraux, JM
    [J]. HEPATOLOGY, 1999, 29 (02) : 528 - 535
  • [6] GENOTYPIC ANALYSIS OF HEPATITIS-C VIRUS IN AMERICAN PATIENTS
    MAHANEY, K
    TEDESCHI, V
    MAERTENS, G
    DIBISCEGLIE, AM
    VERGALLA, J
    HOOFNAGLE, JH
    SALLIE, R
    [J]. HEPATOLOGY, 1994, 20 (06) : 1405 - 1411
  • [7] Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    McHutchison, JG
    Gordon, SC
    Schiff, ER
    Shiffman, ML
    Lee, WM
    Rustgi, VK
    Goodman, ZD
    Ling, MH
    Cort, S
    Albrecht, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1485 - 1492
  • [8] Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays
    Mellor, J
    Hawkins, A
    Simmonds, P
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (08) : 2525 - 2532
  • [9] ORITO E, 1994, J MED VIROL, V44, P410, DOI 10.1002/jmv.1890440418
  • [10] Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
    Saldanha, J
    Lelie, N
    Heath, A
    [J]. VOX SANGUINIS, 1999, 76 (03) : 149 - 158